At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Light-activated AU-011 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma
In Brief
A Phase 2 clinical trial evaluating Light-activated AU-011 and Laser Activation for Uveal Melanoma and 2 related conditions. Completed, enrolled 57 participants across 13 sites.
Detailed Summary
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveal Melanoma, Ocular Melanoma, Choroidal Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartFeb 2017
Primary CompletionJan 2021
TodayJul 2026
First PostedFeb 14, 2017
Enrollment StartFeb 27, 2017
Primary CompletionJan 26, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.4 years ago
Interventions
Light-activated AU-011drug
Study treatment
Laser Activationdevice
Study treatment